| 23.02.2010 | GlycoVaxyn's First Clinical Study with Bioconjugate Vaccine Initiated
GlycoVaxyn has commenced a Phase I clinical study with its vaccine candidate GVXN SD133 against Shigella dysenteriae. |
| 06.10.2009 | GlycoVaxyn Appoints Renowned Vaccinologist Dr. Stanley Plotkin to Supervisory Board
GlycoVaxyn announced today that the world renowned vaccinologist Dr. Stanley A. Plotkin has been elected to its Supervisory Board. |
| 05.03.2009 | GlycoVaxyn Announces its Series B Financing Round
GlycoVaxyn AG raises CHF 25 million in Financing led by Edmond de Rothschild Investment Partners. |
| 20.05.2008 | GlycoVaxyn Appoints Philippe Dro as CEO
GlycoVaxyn AG announces the appointment of Dr. Philippe Dro as Chief Executive Officer and member of the Supervisory Board. Dr. Dro brings to GlycoVaxyn nearly 20 years entrepreneurial experience in the life science industry. |
| 16.07.2007 | Series A Financing and Chairman Appointment
GlycoVaxyn AG completes CHF 11.5 million Series A Financing. Former Aventis Pasteur President Michel Gréco appointed as chairman. |
| 01.06.2007 | GlycoVaxyn has Moved to Zurich-Schlieren
We are very pleased to announce that GlycoVaxyn has moved to larger facilities within the biotech cluster in Zurich-Schlieren. |
| 19.10.2006 | GlycoVaxyn Wins the Life Sciences Prize 2006
GlycoVaxyn was awarded the Life Sciences Prize 2006, which is under the patronage of the Swiss Biotech Association and the BioValley Basel Association, on October 18th, 2006. The prize recognizes the scientific basis and the significant potential of for economic success of young Swiss startup companies. |
| 06.07.2006 | GlycoVaxyn announces its first institutional financing round
GlycoVaxyn announces that it has completed its first institutional financing round in early July 2006, co-led by Index Ventures (www.indexventures.com) and Sofinnova Partners (www.sofinnova.fr). The proceeds from this financing will be used for the validation of GlycoVaxyn’s proprietary bacterial glycosylation technology. The funds are dedicated to advance GlycoVaxyn’ conjugated vaccine development programs against several bacterial pathogens of clinical significance. Furthermore, experimental work will address the widening of the scope of the technology, particularly by including different established carrier proteins as acceptors for bacterial sugar antigens. |
| 01.12.2005 | GlycoVaxyn Has Moved to the Tuwag Areal in Wädenswil
We are very pleased to announce that GlycoVaxyn is a new company located in the grow technology center |
